Halozyme Therapeutics, Inc. (HALO)
HALO Stock Price Chart
Explore Halozyme Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze HALO price movements and trends.
HALO Company Profile
Discover essential business fundamentals and corporate details for Halozyme Therapeutics, Inc. (HALO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Mar 2004
Employees
423.00
Website
https://www.halozyme.comCEO
Helen I. Torley
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
HALO Financial Timeline
Browse a chronological timeline of Halozyme Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $1.82, while revenue estimate is $399.89m.
Earnings released on 11 May 2026
EPS came in at $1.60 surpassing the estimated $1.55 by +3.23%, while revenue for the quarter reached $376.71m , beating expectations by +5.05%.
Earnings released on 17 Feb 2026
EPS came in at -$0.24 falling short of the estimated $2.15 by -111.16%, while revenue for the quarter reached $451.77m , beating expectations by +3.69%.
Earnings released on 3 Nov 2025
EPS came in at $1.72 surpassing the estimated $1.63 by +5.52%, while revenue for the quarter reached $354.26m , missing expectations by -20.66%.
Earnings released on 5 Aug 2025
EPS came in at $1.54 surpassing the estimated $1.23 by +25.20%, while revenue for the quarter reached $325.72m , missing expectations by -1.53%.
Earnings released on 6 May 2025
EPS came in at $1.11 surpassing the estimated $0.95 by +16.84%, while revenue for the quarter reached $264.86m , missing expectations by -5.73%.
Earnings released on 18 Feb 2025
EPS came in at $1.26 surpassing the estimated $1.17 by +7.69%, while revenue for the quarter reached $298.01m , beating expectations by +4.29%.
Earnings released on 31 Oct 2024
EPS came in at $1.27 surpassing the estimated $0.98 by +29.59%, while revenue for the quarter reached $290.08m , missing expectations by -0.94%.
Earnings released on 6 Aug 2024
EPS came in at $0.91 surpassing the estimated $0.76 by +19.74%, while revenue for the quarter reached $231.35m , beating expectations by +10.73%.
Earnings released on 7 May 2024
EPS came in at $0.79 surpassing the estimated $0.70 by +12.86%, while revenue for the quarter reached $195.88m , missing expectations by -1.95%.
Earnings released on 20 Feb 2024
EPS came in at $0.82 falling short of the estimated $0.83 by -1.20%, while revenue for the quarter reached $230.04m , missing expectations by -0.48%.
Earnings released on 6 Nov 2023
EPS came in at $0.75 surpassing the estimated $0.71 by +5.63%, while revenue for the quarter reached $216.03m , missing expectations by -2.96%.
Earnings released on 8 Aug 2023
EPS came in at $0.74 surpassing the estimated $0.63 by +17.46%, while revenue for the quarter reached $221.04m , beating expectations by +10.55%.
Earnings released on 9 May 2023
EPS came in at $0.47 falling short of the estimated $0.48 by -2.08%, while revenue for the quarter reached $162.14m , missing expectations by -7.62%.
Earnings released on 21 Feb 2023
EPS came in at $0.48 surpassing the estimated $0.47 by +2.13%, while revenue for the quarter reached $181.50m , missing expectations by -5.50%.
Earnings released on 8 Nov 2022
EPS came in at $0.74 surpassing the estimated $0.52 by +42.31%, while revenue for the quarter reached $208.98m , beating expectations by +9.31%.
Earnings released on 9 Aug 2022
EPS came in at $0.53 surpassing the estimated $0.50 by +6.00%, while revenue for the quarter reached $152.37m , beating expectations by +9.91%.
Earnings released on 10 May 2022
EPS came in at $0.47 falling short of the estimated $0.49 by -4.08%, while revenue for the quarter reached $117.28m , missing expectations by -8.56%.
Earnings released on 22 Feb 2022
EPS came in at $0.42 surpassing the estimated $0.41 by +2.44%, while revenue for the quarter reached $102.00m , beating expectations by +0.46%.
Earnings released on 2 Nov 2021
EPS came in at $0.55 surpassing the estimated $0.42 by +30.95%, while revenue for the quarter reached $115.83m , beating expectations by +8.29%.
Earnings released on 9 Aug 2021
EPS came in at $0.66 surpassing the estimated $0.43 by +53.49%, while revenue for the quarter reached $136.46m , beating expectations by +31.16%.
HALO Stock Performance
Access detailed HALO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
